All eyes will be on JNJ as it releases its numbers Tuesday.
Stand aside and let things "shake out".
A double in five months has my attention.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.
ProQR Therapeutics, Oscar Health and Hims & Hers Health appear to have promising futures.
After watching the moves in Trillium Therapeutics, a Real Money reader wants to play CRDF. Here's the what the charts say.
Let's see if his intuition is right on ISRG.
Here's how to approach the diagnostics company for both the aggressive and timid.
Let's check the charts and indicators.
Here's why the current weakness in Bionano Genomics could be a buying opportunity.